智通财经APP讯，归创通桥(02190)发布公告，于2025年8月21日，该公司斥资118.35万股回购5万股。 ...

| 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年8月20日 | 318,028,613 | | 4,372,131 | | 322,400,744 | | 1). 購回股份 (股份被持作庫存股份) | | -50,000 | 0.0153 % | 50,000 HKD | 23.67 | | | 變動日期 2025年8月21日 | | | | | | | | 於下列日期結 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company reported a significant increase in revenue and profit, with a 31.7% year-on-year growth in revenue to 482 million yuan and a 76.0% increase in unadjusted profit to 121 million yuan, indicating a strong operational performance [4][5] - The company is benefiting from favorable policies and a shift in the market, particularly in high-end medical devices, which is expected to enhance its competitive position [6] - The international business is poised for growth, with a diverse product portfolio and expansion into emerging markets, contributing to a 36.8% increase in overseas sales [7] Financial Performance Summary - For the first half of 2025, the company achieved a revenue of 482 million yuan, with a gross profit of 343 million yuan and a gross margin of 71.2% [4] - The company’s operational efficiency improved, with a decrease in sales and distribution expenses to 17.7% and R&D expenses to 25.2% of revenue [5] - The company’s cash position is strong, with 2.53 billion yuan in cash on hand [5] Future Projections - Revenue projections for 2025, 2026, and 2027 are 1.059 billion yuan, 1.390 billion yuan, and 1.748 billion yuan, respectively, with expected growth rates of 35%, 31%, and 26% [8] - The net profit for the same years is projected to be 200 million yuan, 303 million yuan, and 463 million yuan, reflecting year-on-year growth of 99%, 52%, and 53% [8] - The expected earnings per share (EPS) for 2025, 2026, and 2027 are 0.61 yuan, 0.92 yuan, and 1.40 yuan, respectively [8]

Core Viewpoint - Guichuang Tongqiao (02190) reported significant growth in its interim results for the six months ending June 30, 2025, with revenue reaching 482 million RMB, a year-on-year increase of 31.69% [1] Financial Performance - Revenue for the period was 482 million RMB, up 31.69% year-on-year [1] - Gross profit amounted to 343 million RMB, reflecting a 31.5% increase compared to the previous year [1] - Shareholder profit attributable to the company was 121 million RMB, marking a substantial increase of 76% year-on-year [1] - Basic earnings per share were reported at 0.38 RMB [1] Business Segmentation - 63.3% of the company's revenue came from neurovascular intervention products, while 36.7% was derived from peripheral vascular intervention products [1] - The significant revenue growth was primarily driven by the rapid sales increase in both neurovascular and peripheral vascular intervention devices [1] Product Performance - Sales revenue from neurovascular intervention products increased by 25.0% in the first half of 2025 compared to the first half of 2024 [1] - Major contributors to this growth included the Silver Snake intracranial intermediate catheter series, Phoenix intracranial aneurysm embolization coils, and neurovascular guidewires [1] - The company launched newer products like the Qilin blood flow guiding device following large-scale centralized procurement in hospitals, enhancing product penetration across various hospital levels [1]

Core Viewpoint - Guichuang Tongqiao (02190) reported significant growth in its interim results for the six months ending June 30, 2025, with revenue reaching 482 million RMB, a year-on-year increase of 31.69% [1] Financial Performance - Revenue for the period was 482 million RMB, up 31.69% year-on-year [1] - Gross profit amounted to 343 million RMB, reflecting a 31.5% increase compared to the previous year [1] - Shareholder profit attributable to the company was 121 million RMB, marking a substantial increase of 76% year-on-year [1] - Basic earnings per share were reported at 0.38 RMB [1] Business Segmentation - 63.3% of the company's revenue came from neurovascular intervention products, while 36.7% was derived from peripheral vascular intervention products [1] - The significant revenue growth was primarily driven by the high sales growth in both neurovascular and peripheral vascular intervention device segments [1] Product Performance - Sales revenue from neurovascular intervention products increased by 25.0% in the first half of 2025 compared to the first half of 2024 [1] - Major contributors to this growth included the Silver Snake intracranial intermediate catheter series, Phoenix intracranial aneurysm embolization coils, and neurovascular guidewires [1] - The company launched newer products like the Qilin blood flow guiding device nationwide following large-scale centralized procurement by hospitals, alongside efforts to enhance product penetration across various hospital levels [1]

Core Viewpoint - Multiple companies, including Tencent Holdings and China Hongqiao, conducted share buybacks on August 20, 2025, with Tencent leading in both volume and monetary value [1]. Group 1: Buyback Details - Tencent Holdings (00700) repurchased 934,000 shares for a total of 551 million [2]. - China Hongqiao (01378) repurchased 3,318,000 shares for a total of 784.03 million [2]. - Other notable buybacks include: - Techtronic Industries (00669): 250,000 shares for 25.19 million [2]. - Hang Seng Bank (00011): 200,000 shares for 22.37 million [2]. - Guochuang Tongqiao-B (02190): 100,000 shares for 2.32 million [2]. Group 2: Year-to-Date Buyback Performance - Year-to-date buyback totals for selected companies include: - Tencent Holdings: 40,267,000 shares, representing 0.438% of total shares [2]. - China Hongqiao: 52,641,500 shares, representing 0.560% of total shares [2]. - Techtronic Industries: 750,000 shares, representing 0.041% of total shares [2]. - Other companies with significant year-to-date buybacks include: - Maple Leaf Education (01317): 4,903,200 shares, representing 1.650% of total shares [2]. - Yanzheng Technology (02488): 2,190,500 shares, representing 1.356% of total shares [2].

Group 1 - The company, Guichuang Tongqiao, repurchased 100,000 shares at an average price of HKD 23.20, totaling approximately HKD 2.32 million, with a cumulative repurchase of 4.0145 million shares this year, representing 1.26% of the total share capital [1] - As of the market close on the same day, Guichuang Tongqiao's stock price decreased by 1.18%, closing at HKD 23.38 per share [1] - Stock repurchase is typically a strategy employed by management when they believe the company's stock is undervalued, indicating confidence in future development despite market perceptions [1] Group 2 - Guichuang Tongqiao is an innovative medical device company listed on the Hong Kong Stock Exchange, focusing on the research, production, and sales of neuro and peripheral vascular interventional medical devices [2] - The company invests significantly in technology research and development, holding a series of proprietary technologies, and its product range includes various interventional medical devices such as stents [2] - With the growing demand for interventional treatments in the medical industry, Guichuang Tongqiao faces opportunities for development while also needing to address market competition and technological advancements [2]

智通财经APP讯，归创通桥(02190)公布，2025年8月20日耗资约232.03万港元回购10万股股份。 ...

Group 1 - The company, Guichuang Tongqiao (02190.HK), announced a share buyback on August 20, 2023, spending HKD 2.32 million to repurchase 100,000 shares [1]

Group 1 - The company, Guichuang Tongqiao (02190), announced a share buyback plan to repurchase 100,000 shares at a cost of approximately HKD 2.3203 million on August 20, 2025 [1]